Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. (original) (raw)

• Journal List
• Proc Natl Acad Sci U S A
• v.89(16); 1992 Aug 15
• PMC49723

Proc Natl Acad Sci U S A. 1992 Aug 15; 89(16): 7427–7431.

Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110.

Abstract

Tissue-type plasminogen activator (t-PA), a serine protease that catalyzes the initial and rate-limiting step in the fibrinolytic cascade, is cleared rapidly in vivo by the liver. Using chemical crosslinking, we have recently identified a plasminogen-activator inhibitor type 1 (PAI-1)-independent t-PA clearance receptor on rat hepatoma MH1C1 cells with a relative molecular mass of approximately 500 kDa. Another recently identified membrane receptor, low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP/alpha 2MR), was also detected on MH1C1 hepatoma cells by using immunoprecipitation with anti-LRP/alpha 2MR antibody. When analyzed by SDS/PAGE, we found the t-PA receptor identified on MH1C1 cells comigrated with the large subunit of LRP/alpha 2MR. The t-PA receptor was immunoprecipitated by an anti-LRP/alpha 2MR antibody after chemical crosslinking of specifically bound 125I-labeled t-PA to its receptor. Through chemical crosslinking studies, we found that t-PA and methylamine-activated alpha 2-macroglobulin could bind to LRP/alpha 2MR simultaneously without competing with one another for binding, suggesting that the two ligands bound to two independent sites on the LRP/alpha 2MR molecule. Furthermore, a 39-kDa protein, which modulates ligand binding to LRP/alpha 2MR, was also found to inhibit t-PA binding to its receptor. These data thus show that the t-PA clearance receptor identified on MH1C1 hepatoma cells is LRP/alpha 2MR.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

• Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981 Jul 10;256(13):7035–7041. [PubMed] [Google Scholar]
• Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. [PubMed] [Google Scholar]
• Bergmann SR, Fox KA, Ter-Pogossian MM, Sobel BE, Collen D. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science. 1983 Jun 10;220(4602):1181–1183. [PubMed] [Google Scholar]
• Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H, Verstraete M, Collen D, Sobel BE. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med. 1984 Mar 8;310(10):609–613. [PubMed] [Google Scholar]
• Lijnen HR, Collen D. Strategies for the improvement of thrombolytic agents. Thromb Haemost. 1991 Jul 12;66(1):88–110. [PubMed] [Google Scholar]
• Korninger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemost. 1981 Oct;46(3):658–661. [PubMed] [Google Scholar]
• Beebe DP, Aronson DL. Turnover of human tissue plasminogen activator (tPA) in rabbits. Thromb Res. 1986 Sep 15;43(6):663–674. [PubMed] [Google Scholar]
• Emeis JJ, van den Hoogen CM, Jense D. Hepatic clearance of tissue-type plasminogen activator in rats. Thromb Haemost. 1985 Oct 30;54(3):661–664. [PubMed] [Google Scholar]
• Rijken DC, Emeis JJ. Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats. Biochem J. 1986 Sep 15;238(3):643–646. [PMC free article] [PubMed] [Google Scholar]
• Fuchs HE, Berger H, Jr, Pizzo SV. Catabolism of human tissue plasminogen activator in mice. Blood. 1985 Mar;65(3):539–544. [PubMed] [Google Scholar]
• Verstraete M, Bounameaux H, de Cock F, Van de Werf F, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther. 1985 Nov;235(2):506–512. [PubMed] [Google Scholar]
• Kuiper J, Otter M, Rijken DC, van Berkel TJ. Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells. J Biol Chem. 1988 Dec 5;263(34):18220–18224. [PubMed] [Google Scholar]
• Owensby DA, Sobel BE, Schwartz AL. Receptor-mediated endocytosis of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. J Biol Chem. 1988 Aug 5;263(22):10587–10594. [PubMed] [Google Scholar]
• Morton PA, Owensby DA, Sobel BE, Schwartz AL. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1. J Biol Chem. 1989 May 5;264(13):7228–7235. [PubMed] [Google Scholar]
• Owensby DA, Morton PA, Schwartz AL. Interactions between tissue-type plasminogen activator and extracellular matrix-associated plasminogen activator inhibitor type 1 in the human hepatoma cell line HepG2. J Biol Chem. 1989 Oct 25;264(30):18180–18187. [PubMed] [Google Scholar]
• Morton PA, Owensby DA, Wun TC, Billadello JJ, Schwartz AL. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells. J Biol Chem. 1990 Aug 25;265(24):14093–14099. [PubMed] [Google Scholar]
• Owensby DA, Morton PA, Wun TC, Schwartz AL. Binding of plasminogen activator inhibitor type-1 to extracellular matrix of Hep G2 cells. Evidence that the binding protein is vitronectin. J Biol Chem. 1991 Mar 5;266(7):4334–4340. [PubMed] [Google Scholar]
• Wing LR, Bennett B, Booth NA. The receptor for tissue plasminogen activator (t-PA) in complex with its inhibitor, PAI-1, on human hepatocytes. FEBS Lett. 1991 Jan 14;278(1):95–97. [PubMed] [Google Scholar]
• Bakhit C, Lewis D, Billings R, Malfroy B. Cellular catabolism of recombinant tissue-type plasminogen activator. Identification and characterization of a novel high affinity uptake system on rat hepatocytes. J Biol Chem. 1987 Jun 25;262(18):8716–8720. [PubMed] [Google Scholar]
• Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J. 1988 Dec 20;7(13):4119–4127. [PMC free article] [PubMed] [Google Scholar]
• Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature. 1989 Sep 14;341(6238):162–164. [PubMed] [Google Scholar]
• Herz J, Kowal RC, Goldstein JL, Brown MS. Proteolytic processing of the 600 kd low density lipoprotein receptor-related protein (LRP) occurs in a trans-Golgi compartment. EMBO J. 1990 Jun;9(6):1769–1776. [PMC free article] [PubMed] [Google Scholar]
• Lund H, Takahashi K, Hamilton RL, Havel RJ. Lipoprotein binding and endosomal itinerary of the low density lipoprotein receptor-related protein in rat liver. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9318–9322. [PMC free article] [PubMed] [Google Scholar]
• Strickland DK, Ashcom JD, Williams S, Burgess WH, Migliorini M, Argraves WS. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem. 1990 Oct 15;265(29):17401–17404. [PubMed] [Google Scholar]
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. [PubMed] [Google Scholar]
• Strickland DK, Ashcom JD, Williams S, Battey F, Behre E, McTigue K, Battey JF, Argraves WS. Primary structure of alpha 2-macroglobulin receptor-associated protein. Human homologue of a Heymann nephritis antigen. J Biol Chem. 1991 Jul 15;266(20):13364–13369. [PubMed] [Google Scholar]
• Herz J, Goldstein JL, Strickland DK, Ho YK, Brown MS. 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J Biol Chem. 1991 Nov 5;266(31):21232–21238. [PubMed] [Google Scholar]
• Williams SE, Ashcom JD, Argraves WS, Strickland DK. A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein. J Biol Chem. 1992 May 5;267(13):9035–9040. [PubMed] [Google Scholar]
• Moestrup SK, Gliemann J. Analysis of ligand recognition by the purified alpha 2-macroglobulin receptor (low density lipoprotein receptor-related protein). Evidence that high affinity of alpha 2-macroglobulin-proteinase complex is achieved by binding to adjacent receptors. J Biol Chem. 1991 Jul 25;266(21):14011–14017. [PubMed] [Google Scholar]
• Smedsrød B, Einarsson M. Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver. Thromb Haemost. 1990 Feb 19;63(1):60–66. [PubMed] [Google Scholar]
• Herz J, Kowal RC, Ho YK, Brown MS, Goldstein JL. Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver. J Biol Chem. 1990 Dec 5;265(34):21355–21362. [PubMed] [Google Scholar]
• Davidsen O, Christensen EI, Gliemann J. The plasma clearance of human alpha 2-macroglobulin-trypsin complex in the rat is mainly accounted for by uptake into hepatocytes. Biochim Biophys Acta. 1985 Jul 30;846(1):85–92. [PubMed] [Google Scholar]
• Südhof TC, Goldstein JL, Brown MS, Russell DW. The LDL receptor gene: a mosaic of exons shared with different proteins. Science. 1985 May 17;228(4701):815–822. [PMC free article] [PubMed] [Google Scholar]
• Raychowdhury R, Niles JL, McCluskey RT, Smith JA. Autoimmune target in Heymann nephritis is a glycoprotein with homology to the LDL receptor. Science. 1989 Jun 9;244(4909):1163–1165. [PubMed] [Google Scholar]
• Yamamoto T, Davis CG, Brown MS, Schneider WJ, Casey ML, Goldstein JL, Russell DW. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell. 1984 Nov;39(1):27–38. [PubMed] [Google Scholar]
• Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986 Apr 4;232(4746):34–47. [PubMed] [Google Scholar]
• Orth K, Madison EL, Gething MJ, Sambrook JF, Herz J. Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7422–7426. [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences